X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA STERLING BIOTECH NATCO PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 33.8 -1.8 - View Chart
P/BV x 17.2 0.1 25,166.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 NATCO PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
STERLING BIOTECH
Dec-13
NATCO PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs87711 8,352.4%   
Low Rs4243 12,455.9%   
Sales per share (Unadj.) Rs223.426.8 833.5%  
Earnings per share (Unadj.) Rs31.1-15.0 -207.7%  
Cash flow per share (Unadj.) Rs40.3-5.5 -737.2%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.554.9 399.9%  
Shares outstanding (eoy) m33.07267.87 12.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.3 1,122.5%   
Avg P/E ratio x20.9-0.5 -4,504.3%  
P/CF ratio (eoy) x16.1-1.3 -1,269.1%  
Price / Book Value ratio x3.00.1 2,339.3%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5041,862 1,155.1%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m1,128547 206.2%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m7,3897,181 102.9%  
Other income Rs m16743 392.3%   
Total revenues Rs m7,5567,223 104.6%   
Gross profit Rs m1,793947 189.4%  
Depreciation Rs m3042,543 12.0%   
Interest Rs m3664,377 8.4%   
Profit before tax Rs m1,290-5,931 -21.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309-1,924 -16.0%   
Profit after tax Rs m1,027-4,007 -25.6%  
Gross profit margin %24.313.2 184.1%  
Effective tax rate %23.932.4 73.8%   
Net profit margin %13.9-55.8 -24.9%  
BALANCE SHEET DATA
Current assets Rs m3,68114,335 25.7%   
Current liabilities Rs m3,12349,809 6.3%   
Net working cap to sales %7.6-494.0 -1.5%  
Current ratio x1.20.3 409.6%  
Inventory Days Days89403 22.2%  
Debtors Days Days59171 34.4%  
Net fixed assets Rs m7,68555,432 13.9%   
Share capital Rs m331268 123.4%   
"Free" reserves Rs m6,67013,935 47.9%   
Net worth Rs m7,25914,701 49.4%   
Long term debt Rs m9559,478 10.1%   
Total assets Rs m11,95773,988 16.2%  
Interest coverage x4.5-0.4 -1,274.0%   
Debt to equity ratio x0.10.6 20.4%  
Sales to assets ratio x0.60.1 636.7%   
Return on assets %11.70.5 2,326.9%  
Return on equity %14.2-27.3 -51.9%  
Return on capital %20.7-6.4 -322.5%  
Exports to sales %39.425.9 151.9%   
Imports to sales %5.70.2 3,355.2%   
Exports (fob) Rs m2,9081,860 156.4%   
Imports (cif) Rs m42112 3,452.5%   
Fx inflow Rs m3,4451,860 185.3%   
Fx outflow Rs m70325 2,823.6%   
Net fx Rs m2,7431,835 149.5%   
CASH FLOW
From Operations Rs m1,4401,719 83.8%  
From Investments Rs m-1,089-3,148 34.6%  
From Financial Activity Rs m-3531,426 -24.7%  
Net Cashflow Rs m-1-3 43.8%  

Share Holding

Indian Promoters % 52.0 33.9 153.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 9.9 168.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 26.0 39.3 66.2%  
Shareholders   25,395 21,482 118.2%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS